Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer


Immune checkpoint blockade therapy by targeting the programmed death protein 1/programmed death ligand 1 (PD-L1) axis using antibodies has yielded promising clinical responses in patients with non-small cell lung cancer (NSCLC). However, owing to the dynamic expression of PD-L1, degree of mutational/neoantigen load, intratumoral heterogeneity, infiltrated… (More)
DOI: 10.1186/s40169-017-0136-7


1 Figure or Table

Slides referencing similar topics